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INTRODUCTION
Intestinal parasitic infections affect more than 2 billion people throughout the world with
disproportionately high prevalence rates in Low- andMiddle-Income Countries (LMICs) (Herricks
et al., 2017). Multicellular and highly complex parasites such as Ascaris, hook worm, Trichuris,
Enterobius and Schistosoma, as well as unicellular organisms including Entamoeba, Giardia,
Toxoplasma, Cyclospora, and Cryptosporidium are among major pathogens that contribute to the
global intestinal parasitic disease burden.
Parasites can cause persistent infection due to their ability to resist immune-mediated expulsion
by modulating the host’s immune response (McSorley and Maizels, 2012; Wammes et al., 2014;
Chabé et al., 2017; Burrows et al., 2019; Ryan et al., 2020). There is a complex interaction between
parasites and human microbiota which can triangulate with host’s immune homeostasis and
host responses to bystander antigens, vaccines or other unrelated diseases, both infectious and
non-communicable diseases (McSorley and Maizels, 2012; Wammes et al., 2014). Recently, the
world has grappled with an unprecedented pandemic due to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19) (WHO,
2020). The pathogenesis of severe disease in COVID-19 has been linked to the phenomenon of
immune hyperactivation (Sinha et al., 2020; Tay et al., 2020). Here, we propose that the interplay
between intestinal parasites and microbiome may have a potential direct or indirect effects on the
pathogenesis of SARS-CoV-2 infection, in particular in the context of LMICs.
PARASITES MODULATE SYSTEMIC IMMUNE RESPONSES
Though enteric parasitic infections can result in severe symptomatic disease, the majority inhabit
the gut of healthy individuals and do not cause obvious signs of inflammation. Parasites have
coevolved with human hosts over thousands of years resulting in persistent modulation of the
immune system, through highly complex and diverse mechanisms (McSorley and Maizels, 2012;
Wammes et al., 2014; Chabé et al., 2017; Burrows et al., 2019; Ryan et al., 2020).
Parasites or their products [known as Excretory Secretory (ES)] are recognized via
microorganism-associated molecular patterns (MAMPs), or pathogen-associated molecular
patterns (PAMPs) (McSorley andMaizels, 2012). The host’s cell pattern-recognition receptors, such
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as toll-like receptors (TLRs), expressed in intestinal lymphoid
cells are able to recognize the various molecular patterns. Overall,
the gut immune response in chronic parasitic infection is
largely T helper (TH) 2 in nature, characterized by activation
of the innate immune system including dendritic cells (DCs),
alternatively activated macrophages (AAMs), regulatory T-
cells (Tregs), regulatory B cells (Bregs), eosinophils, basophils
and mast cells. Cytokines produced by these cells including
interleukin (IL)-4, IL-5, IL-9, IL-10, IL-13, IL-21, IL-25, IL-33,
and transforming growth factor (TGF)-β will have downstream
effects on the CD4+ and CD8+ T-cells of the adaptive immune
system (McSorley andMaizels, 2012;Wammes et al., 2014; Chabé
et al., 2017; Burrows et al., 2019; Ryan et al., 2020).
Parasite-induced immune responses are a “double-edged
sword” as thesemay potentially be detrimental or beneficial to the
host. T-cell hyporesponsiveness induced by helminths may result
in increased susceptibility to infections and reduced responses
to vaccines (Borkow et al., 2000; McSorley and Maizels, 2012;
Wammes et al., 2014). Indeed, deworming in such conditions
has been associated with improved immune responses and/or
clinical outcomes (Elias et al., 2001; Wolday et al., 2002;
Wammes et al., 2014). In addition, intensity of infection is
one of the main factor associated with clinical presentation. In
general, high intensity of infection is associated with pathology
and severe form of clinical presentation. Severe disease can
lead to malnutrition, malabsorption syndrome, micronutrient
deficiency, anemia, stunted growth, organ damage, secondary
bacterial sepsis and death (Jourdan et al., 2018). Another
important factor associated with pathology is the stage of
parasite life cycle. For example, hypersensitivity reaction (Loeffler
syndrome) is commonly associated with the larval stages of
A. lumbricoides and hook worms. Likewise, intestinal mucosal
damage/colitis is linked to the trophozoite stage of E. histolytica.
On the contrary, chronic persistent low intensity infection with
parasites, in particular helminths, can lead to downregulation
of inflammation and reduced disease severity, and deworming
can aggravate the risk of inflammation associated with allergy
and autoimmunity (Wammes et al., 2014). Overall the studies
indicate that parasites have the capacity to suppress pro-
inflammatory responses and augment regulatory pathways, and
in turn may result in suboptimal immunity to infections and
lower prevalence of chronic autoimmune diseases in LMICs
compared with High-Income Countries (HICs) (McSorley and
Maizels, 2012; Wammes et al., 2014; Chabé et al., 2017).
PARASITES MODULATE IMMUNE
RESPONSES THROUGH CHANGES OF
GUT MICROBIOME COMPOSITION
In addition to the direct modulation of the host’s immune
response, parasites can also indirectly manipulate the immune
system through changes in the microbiome. The outstanding
advances made possible through the HumanMicrobiome Project
has transformed our perception of the role of microbiome
in health and disease (Turnbaugh et al., 2007). The human
body harbors trillions of microbiome, which has recently been
shown to play critical role in health and disease (Nicholson
et al., 2012; Kåhrström et al., 2016). The composition of
the microbiome varies in different individuals. Nonetheless,
the majority of the species fall into the phyla of Firmicutes,
Bacteroidetes or Actinobacteria. In general, a more diverse
or complex microbiome at a species level is associated with
healthy states, that is essential for immune homeostasis (Ivanov
and Littman, 2011; Nicholson et al., 2012; Kåhrström et al.,
2016; Belkaid and Harrison, 2017). On the other hand,
perturbations of the gut microbiome, also known as dysbiosis,
has been linked with obesity, diabetes, cardiovascular diseases,
neurological disorders, cancer, inflammatory bowel diseases and
autoimmunity (Kåhrström et al., 2016; Kim et al., 2017). Less
diverse gut microbiome community is seen in these diseases
associated with immune dysregulation, including increases in
traditionally pathogenic bacteria (e.g., Enterobacteriaceae) and
decreases in commensals (e.g., Lactobacillus, Lachnospiraceae,
and Ruminococcaceae) (Nicholson et al., 2012; Kåhrström et al.,
2016). Furthermore, immune dysregulation driven by dysbiosis
in chronic inflammatory diseases is mainly characterized by
dominant TH1 responses (Kim et al., 2017).
Studies that investigated the impact of helminths on
microbiome are mainly from those conducted on experimental
animal models (Reviewed in Brosschot and Reynolds, 2018).
However, there is paucity of data on the interaction between
parasites and human gut microbiome, with only few studies
conducted to date. Individuals residing in in rural settings
of LMICs with little access to sanitation often exhibit high
prevalence of intestinal parasites (Herricks et al., 2017).
These individuals have significantly increased diversity
and composition of microbiome with potentially beneficial
microbiota, although some controversy exists. The first study
undertaken by Cooper et al. (2013) in Ecuador compared gut
microbiome of children residing in rural area. The investigators
showed that no obvious differences in microbiome composition
of children with T. trichiura compared to those who were not
infected. Nonetheless, a decreased abundance of microbiome
species belonging to the Clostridia class of Firmicutes, as well
as a reduction in overall microbial diversity was observed
among children co-infected with both T. trichiura and A.
lumbricoides. To ascertain the causal relationship between
helminthic infection and microbiome diversity, characterizing
the microbiome population following anthelminthic treatment
is required. However, in these children infected with T.
trichiura, anthelmintic treatment did not alter fecal microbiome
composition. In the second study, Lee et al. (2014) compared
microbiome composition in stool samples in helminth-infected
and uninfected controls in rural Malaysia. The investigators
demonstrated that a significant increase in microbiome diversity
amongst individuals with helminth infection. Furthermore, they
noted an increased abundance of microbiome species belonging
to the Paraprevotellaceae family only in those infected with T.
trichiura infection. A study done by Kay et al. (2015) have shown
that Zimbabwean children infected with S. hematobium had
a significantly higher fecal abundance of the genus Prevetella.
Another study by Ramanan et al. (2016) also demonstrated
that helminth-infected individuals in rural Malaysia harbor
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higher diversity of microbiota (Faecalibacterium and Prevotella)
compared to helminth-negative urban residents harboring
an abundance of single Bacteroides spp. Likewise, a study by
Yang et al. (2017) in Taiwan demonstrated that infection with
Enterobius vermicularis is associated with increased diversity of
the gut microbiome. In this study, E. vermicularis infection was
associated with a lowered relative abundance of Fusobacteria and
an enriched proportion ofActinobacteria, including the probiotic
Bifidobacterium. Treatment with mebendazole correlated with a
further increase in bacterial diversity. A study by Jenkins et al.
(2017) also demonstrated that microbial families belonging to
Verrucomicrobiaceae and Enterobacteriaceae showed a trend
toward increased abundance in helminth-infected individuals,
but Leuconostocaceae and Bacteroidaceae showed a relative
increase in helminth-negative and treated patients, respectively.
To date, the most detailed study on the interaction of helminths
and microbiome is the one undertaken by Rosa et al. (2018).
This study, done across very diverse geographical regions in
Indonesia and Liberia, demonstrated significant differences in
composition of the microbiome community between helminth
infected and uninfected individuals. Furthermore, they identified
microbiome-encoded biological functions only in individuals
infected with helminths.
Few studies have also documented the effect of intestinal
protozoa infections on microbiota diversity in humans. Iebba
et al. (2016) demonstrated that infection with E. histolytica
and B. hominis were linked to eubiotic condition. Likewise,
Entamoeba spp. (other than the pathogenic E. histolytica) has
been found to be strongly associated with increased diversity
and composition of the gut microbiota (Audebert et al.,
2016). Higher diversity has also been found in individuals
harboring Blastocystis spp. (Morton et al., 2015). These results
indicate similarities between helminths and protozoa in their
impact on the gut microbiome, and raise the possibility of a
potentially beneficial effect of protozoa on human health. On
the contrary, recent studies from endemic areas have shown
that infection with the pathogenic protozoan E. histolytica and
G. intestinalis alter microbiota composition to a dysbiotic state
(Verma et al., 2012; Morton et al., 2015; Audebert et al.,
2016; Gilchrist et al., 2016; Beatty et al., 2017). Dysbiosis in
these individuals harboring E. histolytica were characterized
by a decrease in Bacteroides, Clostridium coccoides, C. leptum,
Lactobacillus, Campylobacter, Eubacterium and Fusobacteria, but
increase in Bifidobacterium spp., Clostridiales, Ruminococcaceae,
and Prevotella copri.
Overall, the gut microbiome composition in individuals
residing in HICs is usually less diverse than of those in LMICs,
and this has been ascribed to multitude of factors, such as
differences in genetic makeup, diversity of diet, rural vs. urban
residence, over-usage of antibiotics and improved sanitation
(Wammes et al., 2014; Blekhman et al., 2015; Martinez et al.,
2015; Chabé et al., 2017). Nonetheless, in the majority of the
studies noted in the above demonstrate that both helminth-
or protozoa-modified microbiota diversity and shift in their
composition in LMIC settings may lead to a beneficial effect on
health. Whereas, disappearance of the parasites in HICs has led
to increase in the prevalence of chronic inflammatory conditions.
Several reports have also demonstrated that intestinal
parasites modulate the immune response through both
quantitative and qualitative changes of the intestinal microbiome.
Parasites can influence directly the microbiome through their
antigens (or antigen products) or by interfering the homeostasis
within the shared gut milieu. These studies on parasite-
driven microbiota population changes and the resulting
impact on immune modulation are derived mostly from
experimental animal models. For example, infection of mice
with the nematode Heligmosomoides polygyrus, altered gut
microbiota led to systematic increase in pro-inflammatory
cytokine type I interferon (IFN) that protected the mice
against respiratory viral infection (McFarlane et al., 2017).
Alternatively, parasites can alter microbiome diversity and
composition via systemic immune modulation. This notion
was supported by the observation that infection of mice with
helminths promoted colonization of beneficial microbiota
via TH2 immunity (Ramanan et al., 2016). Furthermore, a
study using a primate model of idiopathic chronic diarrhea
(ICD) has demonstrated that experimental administration
of the helminth T. trichiura improved clinical symptoms of
inflammation that was associated with significant changes in the
composition and relative abundance of different gut bacterial
species, downregulation of TH1 and the induction of TH2
immune response (Broadhurst et al., 2012). Others have also
demonstrated that helminth-modified microbiota diversity in
down-regulating inflammation through production of short-
chain fatty acids (SCFAs) with anti-inflammatory effects (Zaiss
et al., 2015; Chudnovskiy et al., 2016). SCFA production by
helminth-modified microbiota likely contributes to the down-
regulation of inflammation through the induction of Tregs
response (Wilson et al., 2005; Arpaia et al., 2013). Importantly,
infection of mice with the nematode Nippostrongylus brasiliensis
is accompanied by significant changes of the gut microbiota
composition, namely Clostridiaceae spp. and results in the
induction of TH2 immune responses and down-regulation of
TH17 immune response (Fricke et al., 2015). Indeed, the basis
for the notion of helminthic therapy (Wammes et al., 2014; Ryan
et al., 2020) emanated from the observed clinical improvements
in subjects with chronic inflammatory conditions who received
experimental infections (Giacomin et al., 2015, 2016).
Similar to the observed helminth-driven microbiota
changes, parasite-modified microbiota effects on diversity
and composition as well as on immune response have been
documented. For example, infection of wild type mice
with Toxoplasma gondii results in the predominance of
Enterobacteriaceae spp., but reduction or elimination of
Bacteroidetes and Firmicutes (Raetz et al., 2013). These changes
in microbial composition triggers an intense TH1 immune
response accompanied by high levels of IFN-
⋊
production. This
in turn results in severe tissue damage, including of Paneth cells
and anti-microbial peptides, a pattern of immunopathology
also seen in patients with inflammatory bowel disease (Frank
et al., 2007). Likewise, infection with pathogenic protozoa G.
intestinalis that alters microbiota composition to a dysbiotic
state, leads to the activation of TLR signaling pathways and
over-production of pro-inflammatory cytokines, including
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IL-1α and IL-1β (Beatty et al., 2017). On the other hand,
colonization of the intestine by Entamoeba spp. (other than
the pathogenic E. histolytica) and Blastocystis spp. has been
found to be strongly associated with increased diversity and
composition of a beneficial gut microbiota (Morton et al., 2015;
Audebert et al., 2016; Iebba et al., 2016). These parasite-driven
microbiome changes are associated with anti-inflammatory
responses (Nourrisson et al., 2014).
Taken together, TH1/TH2 balances and Treg immune
responses are modulated by parasite-associated modifications in
the composition of the so called beneficial intestinal microbiota.
However, dysbiosis of the microbial population (detrimental)
has been associated with chronic inflammation. Hence, specific
beneficial or detrimental outcomes following exposure to
unrelated pathogen is related to specific helminth- or parasite-
driven microbiome changes and the resulting down-stream
immune responses.
IMMUNOPATHOGENESIS OF COVID-19
In December 2019, a cluster of patients with pneumonia of
unknown etiology was linked to a seafood wholesale market
in Wuhan, Hubei Province, China [Wuhan Municipal Health
Commission (WMHC), 2019]. Subsequently, a novel coronavirus
(2019-nCoV) was identified in the patients who developed severe
acute respiratory infection (Zhu et al., 2020). Unprecedented
rapid spread throughout the world occurred and on 30 January
2020, the World Health Organization (WHO) declared that
COVID-19 is a “public-health emergency of international
concern” (WHO, 2020). As of January 20, 2020, more than 96
million cases have been identified with 2 million related deaths
reported (WHO Coronavirus Disease, 2020).
While most people with COVID-19 develop asymptomatic,
or mild uncomplicated illness, ∼14% of infected cases develop
severe disease that requires hospitalization and oxygen support,
and 5% require admission to an intensive care unit (Zhu et al.,
2020). In severe cases, COVID-19 can be complicated by the
acute respiratory distress syndrome (ARDS), sepsis and septic
shock, multi-organ failure, including acute kidney injury and
cardiac injury. Older age and co-morbid diseases are significant
risk factors for severe disease and death.
Following entry to the respiratory tract, SARS-CoV-2
targets airway epithelial cells, alveolar epithelial cells, vascular
endothelial cells and macrophages within the lung. All these cells
express a receptor known as angiotensin-converting enzyme 2
(ACE2) receptor, the target receptor for receptor-binding domain
(RBD) of SARS-CoV-2 (Hoffmann et al., 2020). Cell surface–
associated transmembrane protease serine protease (TMPRSS2)
regulate the binding of RBD to ACE2 receptor that triggers
endocytosis of the SARS-CoV-2, and release of the virus into the
host cells cytoplasm. Once the virus enters the cytoplasm, it will
eventually hijack the host cell’s machinery, initiate replication
and release of new virus particles. The release of damage-
associated molecular patterns along with PAMPs and MAMPs,
and subsequent recognition by the PRRs of the neighboring
airway cells and macrophages triggers the production of pro-
inflammatory cytokines and chemokines, including IL-6, IFN-
γ inducible protein (IP) 10, monocyte chemoattractant protein
(MCP) 1, macrophage inhibitory protein (MIP)1-α and MIP1-
β. For the majority of patients, the initial immune response
is characterized by activation of innate cells and virus-specific
T-cells and B-cells at the site(s) of infection and subsequent
clearance of virus-infected cells and recovery. In contrast, for
those who develop severe disease, the cytokines and chemokines
continue to attract monocytes, macrophages, neutrophils and T
cells to the site of the infection, promoting further inflammation
and uncontrolled production of pro-inflammatory cytokines
(Sinha et al., 2020; Tay et al., 2020). Viral pathogenesis of
severe disease includes marked vascular endothelitis, thrombosis,
and angiogenesis (Ackermann et al., 2020; Varga et al., 2020).
Compared to mild cases, patients with severe COVID-19
have markedly increased levels of pro-inflammatory cytokines,
including IL-1, IL-2, IL-6, IL-8, IL-10, IL-12, IL-17, tumor
necrosis factor (TNF)-α and IFN-γ (Sinha et al., 2020; Tay
et al., 2020). However, compared to non-COVID-19 ARDS, and
patients with bacterial sepsis, cytokine levels are low (Sinha
et al., 2020). Overall, the cytokine dysregulation associated with a
COVID-19 cytokine storm is typical of a TH1 immune response.
Since there are inverse regulation mechanisms between TH1 and
TH2, parasite-driven microbiome changes with TH2 skewed and
Treg immune responses may mute the inflammation associated
with late-stage COVID-19. On the contrary, parasite-induced




Given the recent advent of the SARS-CoV-2 infection, the
relationship between COVID-19 severity and microbiome
diversity and composition is emerging. Recent reports have
demonstrated that gut microbiota composition and diversity
is significantly altered in patients with COVID-19 who
harbored significantly dysbiotic microbiota composition when
compared to healthy individuals (Reviewed in Ferreira et al.,
2021). The microbiome in these patients is predominantly
composed of harmful organisms, such as Streptococcus, Rothia,
Veilonella, and Actinomyces, and decreased levels of beneficial
symbionts, including Agathobacter, Fusicatenibacter, Roseburia,
and Ruminococcaceae. In addition, a significant correlation
was observed between microbial composition and COVID-
19 severity; whereas microbiota that positively correlated
with disease severity belonged to harmful organisms, such
as Firmicutis, Coprobacillus, and Clostridium spp., beneficial
microbiota, including Alistipes ondedonkii and Faecalibacterium
prausnitzii negatively correlated with COVID-19 severity
(Ferreira et al., 2021).
Intestinal epithelium cells, like lung epithelium cells, expresses
the ACE2 receptor (Lamers et al., 2020). Intestinal epithelium
cells that are in direct contact with microbiota can thus
be infected with SARS-CoV-2. In addition, reports have
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demonstrated that gastrointestinal symptoms such as diarrhea
appear to be frequent in a significant proportion of COVID-19
patients (≈20%) with a prolonged shedding of viral genome in
the feces, in particular in pediatric age group (Xiao et al., 2020;
Xu et al., 2020). The immune responses elicited in the intestinal
epithelium are similar as in the lung (Stanifer et al., 2020). Thus,
it is plausible that the intestinal immune response to SARS-
CoV-2 gut may modulate microbiome composition in the same
intestinal niche. This notion is supported by findings that showed
that gut microbiota of patients with active SARS-CoV-2 infection
of the gastrointestinal tract was characterized by enrichment of
opportunistic pathogens, such as Collinsella spp., Streptoccoccus,
andMorganella (Zuo et al., 2020a,b).
Alternatively, crosstalk between gut microbiome and the lung,
also known as the “gut-lung” axis, may modulated immune
homeostasis and disease development in either compartment
(Enaud et al., 2020). Thus, alteration of themicrobiome in the gut
may influence remotely bothmicrobial composition and immune
response generated in the lung to SARS-CoV-2 and impact on
COVID-19 severity.
IMPACT OF PARASITE-DRIVEN
MICROBIOME CHANGE ON THE
PATHOGENESIS OF COVID-19
Over many years our group has undertaken extensive
investigations on the immunological profile of “apparently”
healthy individuals in Ethiopia – a LIC in Africa. The immune
profile of healthy Ethiopians shows evidence of chronic immune
activation with significant low naïve cells but high activated
memory cells, of both CD4+ and CD8+ T-cell subpopulations
(Borkow et al., 2000; Hazenberg et al., 2000; Kassu et al., 2003;
Tsegaye et al., 2003). Such immune characteristics in Ethiopians
as compared to Europeans led us to the assumption that these
could contribute to the phenomenon of milder COVID-19
symptomatology, as commonly found in SSA and elsewhere in
the world (Chatterjee et al., 2020; Ssebambulidde et al., 2020).
The postulation is that persistent immune activation due to
continuous infections with parasites skews the immune system
of populations in LMICs toward TH2 type and Treg immune
responses that counteract the symptomatology associated with
TH1 hyperinflammation.
Interestingly, gut microbiome disturbance has been shown to
reduce host antiviral immune response, thereby aggravating lung
injury caused by influenza (Ichinohe et al., 2011). In addition,
it has been suggested in several reports that co-infection with
helminths might increase the severity of COVID-19 in helminth-
endemic areas (Bradbury et al., 2020; Gutman et al., 2020).
On one hand, down regulation of the host’s immune response
through parasite-induced microbiome changes may result in
suboptimal antiviral immunity, resulting in increased SARS-
CoV-2 replication. Along these lines, it was suggested that the
“potential negative effects may influence recommendations on
deworming” (Hays et al., 2020). On the other hand, intestinal
parasites may down-regulate the host immune and chronic
inflammatory conditions, such as autoimmunity (McSorley and
Maizels, 2012; Wammes et al., 2014; Chabé et al., 2017; Burrows
et al., 2019; Ryan et al., 2020), potentially protecting from
severe COVID-19. A recent study demonstrated that individuals
with diabetes and helminth coinfection from India exhibited
reduced levels of TH1, TH17 and proinflammatory cytokines,
but increased TH2 and Treg immune responses (Rajamanickam
et al., 2020). This effect was reversed partially following a 6-
month anthelminthic treatment. In addition, several clinical trials
have been carried out or are underway assessing the utility of
using helminths as therapeutic agents in patients with chronic
autoimmune conditions (Ryan et al., 2020).
The pathogenesis of severe COVID-19 leading to
hyperinflammation resembles that of chronic inflammatory
condition, such as hypertension, obesity, diabetes and
inflammatory bowel diseases (Shaw et al., 2016; Fang et al.,
2020). Since parasite-induced alterations of the gut microbiome
has remote immunomodulatory effect on the lung, the resulting
down-regulatory effects might mute the potential deleterious
effects of a hyperactive immune response linked to severe
COVID-19. This notion is supported by the fact that enteric
helminth protect against pulmonary virus infection through
interaction with microbiota (McFarlane et al., 2017). Though
Bradbury et al. (2020) suggest that helminth co-infection might
hasten COVID-19 severity, an alternative hypotheses suggested
that helminths might indeed reduce the severity of SARS-CoV-2
infection (Fonte et al., 2020; Hays et al., 2020; Mbow et al., 2020).
The later hypotheses are corroborated by the observed low
fatality rate of COVID-19 in SSA setting and elsewhere in LMICs
with potential high parasite loads (Fonte et al., 2020; Mbow
et al., 2020). Furthermore, the proponents of this hypotheses
suggest to explore the effects of experimental helminth infection
(EHI) on COVID-19 severity (Hays et al., 2020). Given the
fact that parasite-driven immunological responses and their
reversal by deworming takes several months to exert significant
immunological changes (Colombo and Grencis, 2020), we do
not expect, however, a significant therapeutic impact on an acute
infection with SARS-CoV-2.
Parasites have complex interactions with the host, with
different species and even different stages of parasite life cycle
exerting differential immune responses in the host. Here we
argue that parasitic coinfections could be either beneficial or
detrimental to COVID-19 severity (Figure 1). Certain parasites,
such as commensal Entamoeba spp. and helminths that are
correlated with high bacterial diversity and dominant TH2
and Treg pre-existing profile, might mute hyperactive immune
response upon infection with SARS-CoV-2. On the contrary,
parasites that correlate with dysbiotic microbiota, such as those
observed in pathogenic E. histolytica infection, reminiscent of the
gut microbiome profile of individuals with chronic inflammatory
conditions, might facilitate hyperinflammation and aggravate
COVID-19 severity.
CONCLUSION
Parasite-driven gut microbiome perturbation may alter immune
response to SARS-CoV-2 infection, in particular in settings where
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FIGURE 1 | Impact of parasite-driven microbiome diversity and composition on COVID-19 severity. Certain protozoa, such as commensal Entamoeba spp. and
cryptosporidium spp. and helminths that enrich the gut with the so called beneficial microbiome profile and with dominant TH2 and Treg pre-existing condition, might
mute hyperactive immune response upon infection with SARS-CoV-2. In this milieu, SARS-CoV-2 replication is controlled. Another possibility is that TH2 and Treg
responses might suppress anti-SARS-CoV-2 immunity and thereby hasten COVID-19 severity. On the contrary, gut dysbiosis as a result of some pathogenic protozoa,
such as Entamoeba histolytica or helminths, or patients without parasite coinfection with underlying preexisting THl immune response might facilitate cytokine storm
and aggravate COVID-19 severity. In patients with gut dysbiosis, SARS-CoV-2 replication is significantly increased. AAM/M2 Mø, alternatively-activated macrophages;
Breg, regulatory B cell; ES, Excretory/Secretory parasite product; IFN, interferon; IL, interleukin; IP, interferon-γ-inducible protein; MCP, monocyte chemoattractant
protein; MIP, macrophage inhibitory protein; Mø, macrophage; RBC, red blood cells; TH, T helper lymphocytes; TGF, transformation growth factor; TNF, tumor
necrosis factor; Treg, regulatory T cell.
parasitic infections are highly prevalent, such as SSA. The effect of
parasite coinfection on the pathogenesis of COVID-19 remains
to be elucidated. Chronic parasitic infection is common in
LMICs. Such chronic infections can also indirectly manipulate
the immune system through changes in the microbiota. Thus,
pre-existing parasite infections may modify the host’s immune
response to SARS-CoV-2 with potential beneficial or detrimental
effects – a “double-edged” sword. Future studies in LMIC settings
should explore the effects of coinfection with parasites on the
clinical course of COVID-19 outcomes. Understanding of the
interplay between parasites and the microbiome and its role in
the pathogenesis of COVID-19 will be important, also in light
of future application of vaccine programs as well as therapeutic
strategies (Margolin et al., 2020).
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